{"id":6691,"date":"2022-11-10T07:30:00","date_gmt":"2022-11-10T07:30:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/"},"modified":"2022-11-10T07:30:00","modified_gmt":"2022-11-10T07:30:00","slug":"valberedning-infor-nanexa-ab-publ-arsstamma-2023","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/","title":{"rendered":"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Valberedning har utsetts i Nanexa AB (publ) inf\u00f6r \u00e5rsst\u00e4mman 2023 i enlighet med de principer som beslutades av Nanexas \u00e5rsst\u00e4mma 9 juni 2022.<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p>Valberedningens ledam\u00f6ter utses av de tre r\u00f6stm\u00e4ssigt st\u00f6rsta aktie\u00e4garna i bolaget per den 30 september 2022. F\u00f6r det fall n\u00e5gon av de tre st\u00f6rsta aktie\u00e4garna inte \u00f6nskar utse en ledamot ska den fj\u00e4rde st\u00f6rsta aktie\u00e4garen tillfr\u00e5gas och s\u00e5 vidare intill dess att valberedningen best\u00e5r av tre ledam\u00f6ter. Styrelsens ordf\u00f6rande ska adjungeras till valberedningen.<\/p>\n<p>Inf\u00f6r 2023 har det inte skett n\u00e5gra f\u00f6r\u00e4ndringar i f\u00f6rslag till ledam\u00f6ter, valberedningens ledam\u00f6ter utg\u00f6rs d\u00e4rf\u00f6r av:<\/p>\n<ul>\n<li>Philip Norin<\/li>\n<li>Hanno Lindroth, utsedd av M\u00e5rten Rooth<\/li>\n<li>Christian \u00d6stberg, utsedd av Anders Johansson<\/li>\n<li>G\u00f6ran Ando, styrelseordf\u00f6rande, adjungerad<\/li>\n<\/ul>\n<p>Valberedningens f\u00f6rslag presenteras i kallelsen till \u00e5rsst\u00e4mman 2023 samt p\u00e5 bolagets hemsida, <a href=\"http:\/\/www.nanexa.com\/\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a>.<\/p>\n<p>Aktie\u00e4gare kan kontakta valberedning med f\u00f6rslag avseende dess arbete genom att s\u00e4nda e-mail till info@nanexa.se (rubrik \u201dNanexas valberedning\u201d) eller via brev till: Nanexa AB, Att: Nanexas valberedning, Virdings All\u00e9 2, SE-754 50, Uppsala, Sverige. Datum f\u00f6r \u00e5rsst\u00e4mman 2023 och senaste datum f\u00f6r inl\u00e4mnande av f\u00f6rslag till valberedningen meddelas p\u00e5 Nanexas hemsida innan utg\u00e5ngen av 2022.<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts mfn-2376405b3437\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr \/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a target=\"_blank\" href=\"mailto:david.westberg@nanexa.se\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a href=\"http:\/\/www.nanexa.com\" target=\"_blank\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about mfn-c9ba281e2dde\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr \/>\n<p>Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr \/>\n<p><a class=\"mfn-generated mfn-primary\" href=\"https:\/\/storage.mfn.se\/776cbdad-8377-41e6-a347-525e10d15f27\/valberedning-infor-nanexa-ab-publ-arsstamma-2023.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Valberedning har utsetts i Nanexa AB (publ) inf\u00f6r \u00e5rsst\u00e4mman 2023 i enlighet med de principer som beslutades av Nanexas \u00e5rsst\u00e4mma 9 juni 2022.<\/p>\n","protected":false},"template":"","class_list":["post-6691","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-listing_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv","mfn-news-tag-mfn-ci-nomination_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Valberedning har utsetts i Nanexa AB (publ) inf\u00f6r \u00e5rsst\u00e4mman 2023 i enlighet med de principer som beslutades av Nanexas \u00e5rsst\u00e4mma 9 juni 2022.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\\\/\",\"name\":\"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-11-10T07:30:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/","og_locale":"sv_SE","og_type":"article","og_title":"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023 - Nanexa AB","og_description":"Valberedning har utsetts i Nanexa AB (publ) inf\u00f6r \u00e5rsst\u00e4mman 2023 i enlighet med de principer som beslutades av Nanexas \u00e5rsst\u00e4mma 9 juni 2022.","og_url":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/","url":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/","name":"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-11-10T07:30:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/valberedning-infor-nanexa-ab-publ-arsstamma-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Valberedning inf\u00f6r Nanexa AB (publ) \u00e5rsst\u00e4mma 2023"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6691","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6691"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}